Novo Nordisk’ chief executive Lars Fruergaard ... be the only industry representative in the GLP-1 agonist market to testify at the hearing. AstraZeneca's run of positive trial results with ...

Novo Nordisk has reached an agreement to buy Germany ... people living with heart failure,” continued Dr Lange. Bayer's CEO says new product launches will offset the decline in sales of ...

Novo Nordisk's (NVO) investors are worried its competition ... according to the latest prescription data last month. But Novo CEO Lars Jørgensen attributes the softness in sales to the copycats ...

Novo Nordisk CEO Lars Fruergaard Jørgensen attributed the reduced forecast to rising competition from compounded weight loss drugs in the U.S. "In the first quarter of 2025, we delivered 18% ...

COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO ...

"We’re excited to work with Novo Nordisk, a company known for breakthrough innovation in clinical medicine and a strong portfolio of medications," Hims & Hers CEO Andrew Dudum said in a statement.

Drugmaker Novo Nordisk NVO-N expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after ...

Novo Nordisk's (NVO) investors are worried its competition ... according to the latest prescription data last month. But Novo CEO Lars Jørgensen attributes the softness in sales to the copycats ...

Operating profit growth is forecast at 16% to 24%, versus 19% to 27% previously. Novo Nordisk CEO Lars Fruergaard Jørgensen attributed the reduced forecast to rising competition from compounded ...

"Growth is expected to pick up in the second-half of the year," CEO Lars Fruergaard Jorgensen said on a call with journalists. Novo Nordisk said first-quarter sales of Wegovy were 17.36 billion ...

Novo Nordisk CEO Lars Fruergaard Jørgensen attributed the reduced forecast to rising competition from compounded weight loss drugs in the U.S. "In the first quarter of 2025, we delivered 18% ...